219 related articles for article (PubMed ID: 28121555)
1. Patent litigation could make 2017 no 'dancing' matter.
Reinke T
Manag Care; 2016 Dec; 25(12):23-28. PubMed ID: 28121555
[TBL] [Abstract][Full Text] [Related]
2. Biosimilars in the United States: Emerging Issues in Litigation.
Wong AY; Rumore MM; Chan AW
BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
[TBL] [Abstract][Full Text] [Related]
3. Biosimilar Makers Hope Court Starts 6-Month Wait Sooner.
Silverman E
Manag Care; 2017 Mar; 26(3):31. PubMed ID: 28510518
[TBL] [Abstract][Full Text] [Related]
4. Why Are Biosimilars Not Living up to Their Promise in the US?
Zhai MZ; Sarpatwari A; Kesselheim AS
AMA J Ethics; 2019 Aug; 21(8):E668-678. PubMed ID: 31397662
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars: impact of differences with Hatch-Waxman.
Kowalchyk K; Crowley-Weber C
Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968
[TBL] [Abstract][Full Text] [Related]
6. Patent watch: Have the biosimilar floodgates been opened in the United States?
Brinckerhoff CC; Schorr K
Nat Rev Drug Discov; 2015 May; 14(5):303-4. PubMed ID: 25924576
[No Abstract] [Full Text] [Related]
7. Biosimilars battle rages on, Amgen fights both sides.
Senior M
Nat Biotechnol; 2013 Apr; 31(4):269-70. PubMed ID: 23563402
[No Abstract] [Full Text] [Related]
8. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
[TBL] [Abstract][Full Text] [Related]
9. 10 years of biosimilars: lessons and trends.
Royzman I; Shah K
Nat Rev Drug Discov; 2020 Jun; 19(6):375. PubMed ID: 32358591
[No Abstract] [Full Text] [Related]
10. Special patent provisions for pharmaceuticals: have they outlived their usefulness? A political, legislative and legal history of U.S. law and observations for the future.
Engelberg AB
Spec Law Dig Health Care Law; 2000 Sep; (258):9-48. PubMed ID: 11184791
[No Abstract] [Full Text] [Related]
11. Hatch-Waxman in the Federal Courts: from 1994--2004.
Ludwig SP; Kosinski KB; Harris J
Drug Dev Ind Pharm; 2005 Jan; 31(2):215-22. PubMed ID: 15773288
[TBL] [Abstract][Full Text] [Related]
12. FDA's proposed rules on patent listing requirements for new drug and 30-month stays on ANDA approval (proposed Oct. 24, 2002).
Hui YF
Ann Health Law; 2003; 12(2):325-40, table of contents. PubMed ID: 12856462
[TBL] [Abstract][Full Text] [Related]
13. A cheat sheet to navigate the complex maze of exclusivities in the United States.
Peng B; Tomas MC
Pharm Pat Anal; 2014 Jul; 3(4):339-43. PubMed ID: 25291306
[No Abstract] [Full Text] [Related]
14. Patent infringement. Generic HIV drugmaker's patent claim is time-barred.
AIDS Policy Law; 2003 Aug; 18(16):6. PubMed ID: 14626916
[No Abstract] [Full Text] [Related]
15. The application of the patent laws to the drug approval process.
Coggio BD; Cerrito FD
Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669
[No Abstract] [Full Text] [Related]
16. Korea: the new first battleground for the high stakes poker game of pharmaceutical patent litigation.
Choe JY; Yoon KA; Lee S
Pharm Pat Anal; 2015; 4(6):409-13. PubMed ID: 26580988
[No Abstract] [Full Text] [Related]
17. Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.
Chen BK; Yang YT; Bennett CL
Drugs; 2018 Nov; 78(17):1777-1781. PubMed ID: 30446980
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars: how similar?
Strand V; Cronstein B
Intern Med J; 2014 Mar; 44(3):218-23. PubMed ID: 24118772
[TBL] [Abstract][Full Text] [Related]
19. Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS.
Kim J; Ross JS; Kapczynski A
JAMA; 2018 Jan; 319(1):21-22. PubMed ID: 29117365
[No Abstract] [Full Text] [Related]
20. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
McPhie DC
Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
[No Abstract] [Full Text] [Related]
[Next] [New Search]
